Intact Investment Management Inc. Raises Position in DexCom, Inc. (NASDAQ:DXCM)

Intact Investment Management Inc. lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 23.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,000 shares of the medical device company’s stock after purchasing an additional 2,300 shares during the period. Intact Investment Management Inc.’s holdings in DexCom were worth $933,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of DXCM. Jennison Associates LLC increased its stake in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Congress Asset Management Co. boosted its holdings in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after buying an additional 1,332,522 shares during the period. Fisher Funds Management LTD bought a new position in DexCom in the 4th quarter worth approximately $96,507,000. Westfield Capital Management Co. LP boosted its holdings in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after buying an additional 876,739 shares during the period. Finally, Two Sigma Advisers LP boosted its holdings in DexCom by 182.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after buying an additional 739,000 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares in the company, valued at $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 104,657 shares of company stock worth $8,019,422 in the last 90 days. 0.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DXCM. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Canaccord Genuity Group raised their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $70.69 on Friday. The stock has a market cap of $27.62 billion, a PE ratio of 49.43, a PEG ratio of 2.30 and a beta of 1.28. The company’s fifty day moving average is $83.99 and its 200 day moving average is $76.89. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.